Talphera (NASDAQ:TLPH – Get Free Report) and Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
37.7% of Talphera shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Talphera and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -87.28% | -51.36% |
| Vanda Pharmaceuticals | -119.87% | -58.37% | -36.21% |
Risk and Volatility
Talphera has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Earnings & Valuation
This table compares Talphera and Vanda Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talphera | $30,000.00 | 1,747.64 | -$14.29 million | ($0.27) | -3.74 |
| Vanda Pharmaceuticals | $216.10 million | 1.09 | -$220.47 million | ($4.62) | -0.84 |
Talphera has higher earnings, but lower revenue than Vanda Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Talphera and Vanda Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
| Vanda Pharmaceuticals | 2 | 1 | 6 | 0 | 2.44 |
Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 197.03%. Vanda Pharmaceuticals has a consensus target price of $13.50, suggesting a potential upside of 247.94%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Talphera.
Summary
Vanda Pharmaceuticals beats Talphera on 9 of the 13 factors compared between the two stocks.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
